Cargando…
Therapeutic Plasma Exchange: A potential Management Strategy for Critically Ill COVID-19 Patients
In the 5 months since initial reports of COVID-19 came to light, the death toll due to SARS-CoV-2 has rapidly increased. The morbidity and mortality of the infection varies based upon patient age, comorbid conditions, viral load, and the availability of effective treatments. Findings from limited au...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7391476/ https://www.ncbi.nlm.nih.gov/pubmed/32666875 http://dx.doi.org/10.1177/0885066620940259 |
_version_ | 1783564643441049600 |
---|---|
author | Tabibi, Seena Tabibi, Tara Conic, Rosalynn R. Z. Banisaeed, Nassim Streiff, Michael B. |
author_facet | Tabibi, Seena Tabibi, Tara Conic, Rosalynn R. Z. Banisaeed, Nassim Streiff, Michael B. |
author_sort | Tabibi, Seena |
collection | PubMed |
description | In the 5 months since initial reports of COVID-19 came to light, the death toll due to SARS-CoV-2 has rapidly increased. The morbidity and mortality of the infection varies based upon patient age, comorbid conditions, viral load, and the availability of effective treatments. Findings from limited autopsies, clinical observations, and laboratory data suggest that high cytokine levels and a procoagulant state can precipitate acute respiratory distress syndrome and multi-organ dysfunction syndrome in critically ill patients. To complicate matters, comorbidities may affect the response to medical treatments currently in use, all of which are still in trial phase. Therapeutic plasma exchange (TPE) merits consideration in the treatment of critically ill COVID-19 patients and is an avenue for clinical trials to pursue. If efficacious, faster recovery of patients may lead to shorter intensive care unit stays and less time on mechanical ventilation. Herein, we briefly discuss some of the various approaches currently being investigated for the treatment of SARS-CoV-2 with a focus on potential benefits of TPE for selected critically ill patients. |
format | Online Article Text |
id | pubmed-7391476 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-73914762020-08-14 Therapeutic Plasma Exchange: A potential Management Strategy for Critically Ill COVID-19 Patients Tabibi, Seena Tabibi, Tara Conic, Rosalynn R. Z. Banisaeed, Nassim Streiff, Michael B. J Intensive Care Med Analytic Review In the 5 months since initial reports of COVID-19 came to light, the death toll due to SARS-CoV-2 has rapidly increased. The morbidity and mortality of the infection varies based upon patient age, comorbid conditions, viral load, and the availability of effective treatments. Findings from limited autopsies, clinical observations, and laboratory data suggest that high cytokine levels and a procoagulant state can precipitate acute respiratory distress syndrome and multi-organ dysfunction syndrome in critically ill patients. To complicate matters, comorbidities may affect the response to medical treatments currently in use, all of which are still in trial phase. Therapeutic plasma exchange (TPE) merits consideration in the treatment of critically ill COVID-19 patients and is an avenue for clinical trials to pursue. If efficacious, faster recovery of patients may lead to shorter intensive care unit stays and less time on mechanical ventilation. Herein, we briefly discuss some of the various approaches currently being investigated for the treatment of SARS-CoV-2 with a focus on potential benefits of TPE for selected critically ill patients. SAGE Publications 2020-07-15 2020-09 /pmc/articles/PMC7391476/ /pubmed/32666875 http://dx.doi.org/10.1177/0885066620940259 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Analytic Review Tabibi, Seena Tabibi, Tara Conic, Rosalynn R. Z. Banisaeed, Nassim Streiff, Michael B. Therapeutic Plasma Exchange: A potential Management Strategy for Critically Ill COVID-19 Patients |
title | Therapeutic Plasma Exchange: A potential Management Strategy for Critically Ill COVID-19 Patients |
title_full | Therapeutic Plasma Exchange: A potential Management Strategy for Critically Ill COVID-19 Patients |
title_fullStr | Therapeutic Plasma Exchange: A potential Management Strategy for Critically Ill COVID-19 Patients |
title_full_unstemmed | Therapeutic Plasma Exchange: A potential Management Strategy for Critically Ill COVID-19 Patients |
title_short | Therapeutic Plasma Exchange: A potential Management Strategy for Critically Ill COVID-19 Patients |
title_sort | therapeutic plasma exchange: a potential management strategy for critically ill covid-19 patients |
topic | Analytic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7391476/ https://www.ncbi.nlm.nih.gov/pubmed/32666875 http://dx.doi.org/10.1177/0885066620940259 |
work_keys_str_mv | AT tabibiseena therapeuticplasmaexchangeapotentialmanagementstrategyforcriticallyillcovid19patients AT tabibitara therapeuticplasmaexchangeapotentialmanagementstrategyforcriticallyillcovid19patients AT conicrosalynnrz therapeuticplasmaexchangeapotentialmanagementstrategyforcriticallyillcovid19patients AT banisaeednassim therapeuticplasmaexchangeapotentialmanagementstrategyforcriticallyillcovid19patients AT streiffmichaelb therapeuticplasmaexchangeapotentialmanagementstrategyforcriticallyillcovid19patients |